TherapeuticsMD Inc (TXMD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, TherapeuticsMD Inc (TXMD) has a cash flow conversion efficiency ratio of 0.051x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.37 Million) by net assets ($26.88 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See TXMD equity to assets ratio to measure how much of total assets are equity-financed.
TherapeuticsMD Inc - Cash Flow Conversion Efficiency Trend (1994–2025)
This chart illustrates how TherapeuticsMD Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check TXMD cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
TherapeuticsMD Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of TherapeuticsMD Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
NamSys Inc
V:CTZ
|
0.102x |
|
Wing Yip Food Holdings Group Limited American Depositary Shares
NASDAQ:WYHG
|
0.026x |
|
Damai Sejahtera Abadi Tbk PT
JK:UFOE
|
0.101x |
|
YBS International Bhd
KLSE:0025
|
0.020x |
|
Pudjiadi & Sons Tbk
JK:PNSE
|
0.115x |
|
Master Pack Group Bhd
KLSE:7029
|
0.021x |
|
Andromeda Metals Ltd
AU:ADN
|
-0.013x |
|
Pulsenmore Ltd
TA:PULS
|
-0.196x |
Annual Cash Flow Conversion Efficiency for TherapeuticsMD Inc (1994–2025)
The table below shows the annual cash flow conversion efficiency of TherapeuticsMD Inc from 1994 to 2025. For the full company profile with market capitalisation and key ratios, see TherapeuticsMD Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $26.88 Million | $2.45 Million | 0.091x | +241.41% |
| 2024-12-31 | $27.37 Million | $732.00K | 0.027x | +101.63% |
| 2023-12-31 | $29.29 Million | $-48.14 Million | -1.644x | -1316.55% |
| 2022-12-31 | $35.14 Million | $-4.08 Million | -0.116x | -107.35% |
| 2021-12-31 | $-93.62 Million | $-147.81 Million | 1.579x | +22.77% |
| 2020-12-31 | $-124.00 Million | $-159.47 Million | 1.286x | +107.14% |
| 2019-12-31 | $9.20 Million | $-165.70 Million | -18.008x | -1544.25% |
| 2018-12-31 | $97.52 Million | $-106.81 Million | -1.095x | -86.83% |
| 2017-12-31 | $129.91 Million | $-76.16 Million | -0.586x | -8.09% |
| 2016-12-31 | $127.49 Million | $-69.14 Million | -0.542x | +56.73% |
| 2015-12-31 | $63.06 Million | $-79.04 Million | -1.253x | -33.24% |
| 2014-12-31 | $48.39 Million | $-45.52 Million | -0.941x | -147.77% |
| 2013-12-31 | $54.70 Million | $-20.77 Million | -0.380x | -104.27% |
| 2012-12-31 | $-1.43 Million | $-12.74 Million | 8.888x | +206.34% |
| 2011-12-31 | $-1.71 Million | $-4.97 Million | 2.901x | +414.65% |
| 2010-12-31 | $-907.55K | $836.83K | -0.922x | -168.72% |
| 2009-12-31 | $-311.05K | $-417.34K | 1.342x | +118.86% |
| 2008-12-31 | $18.70K | $-133.00K | -7.114x | -963.18% |
| 2007-12-31 | $417.54K | $344.10K | 0.824x | +321.58% |
| 2006-12-31 | $1.69 Million | $329.84K | 0.195x | -37.69% |
| 2005-12-31 | $1.31 Million | $412.34K | 0.314x | +58.80% |
| 2004-12-31 | $1.05 Million | $207.73K | 0.198x | +22.22% |
| 2003-12-31 | $866.11K | $140.00K | 0.162x | +18.95% |
| 2002-12-31 | $736.41K | $100.08K | 0.136x | -43.60% |
| 2001-12-31 | $672.09K | $161.95K | 0.241x | +10.07% |
| 2000-12-31 | $611.97K | $133.97K | 0.219x | +116.68% |
| 1999-12-31 | $480.35K | $48.53K | 0.101x | +3.79% |
| 1998-12-31 | $458.12K | $44.60K | 0.097x | -37.48% |
| 1997-12-31 | $497.89K | $77.53K | 0.156x | +35.32% |
| 1996-12-31 | $510.88K | $58.78K | 0.115x | -20.11% |
| 1995-12-31 | $440.53K | $63.45K | 0.144x | -17.20% |
| 1994-12-31 | $418.86K | $72.86K | 0.174x | -- |
About TherapeuticsMD Inc
TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States and internationally. Its products portfolio includes IMVEXXY for the treatment of moderate-to-severe dyspareunia, a symptom of vulvar and vaginal atrophy due to menopause; BIJUVA to treat moderate-to-severe vasomotor symptoms due to menopause in women with a uterus; and ANNOVERA, a ring-shaped contraceptive vag… Read more